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Abstract
Background: The long-term neurological consequences of HIV infection and treatment are not yet completely
understood. In this study we examined the prevalence of cerebral metabolic abnormalities among a cohort of
neurologically intact HIV patients with fully suppressed HIV viral loads. Concomitant analyses of circulating brain
derived neurotrophic factor (BDNF) were performed to correlate these abnormalities with potential signs of neuro-
regenerating/protective activity, and concomitant analyses of circulating tumour necrosis factor (TNF) a, interleukin
(IL) 6, and soluble urokinase plasminogen activator receptor (suPAR) were performed to correlate these
abnormalities with potential signs of neurodegenerative processes.
Methods: The study population consisted of HIV-positive patients known to be infected for more than 5 years and
on antiretroviral (ARV) treatment for a minimum of three years with no history of virological failure, a CD4 count
above 200 × 10
6 cells/l and no other co-morbidities. The distribution of the regional cerebral metabolic rate of
glucose metabolism was measured using fluorine-18-flourodeoxyglucose positron emission tomography (FDG-PET)
scanning. The PET scans were evaluated for individual pathology using Neurostat software and for group
pathology using statistical parametric mapping (SPM). Circulating levels of BDNF, TNF a, IL-6 and suPAR were
measured by ELISA techniques.
Results: More than half (55%) of the patients exhibited varying severities of mesial frontal reduction in the relative
metabolic rate of glucose. Compared to healthy subjects, the patients with abnormal FDG-PET scanning results had
a shorter history of known HIV infection, fewer years on antiretroviral therapy and higher levels of circulating TNF a
and IL-6 (p = 0.08).
Conclusion: A large proportion of optimally treated HIV patients exhibit cerebral FDG-PET scanning abnormalities
and elevated TNF a and IL-6 levels, which may indicate imminent neuronal damage. The neuroprotective effect of
early ARV treatment should be considered in future prospective follow-up studies.
Background
Human immunodeficiency virus (HIV) 1 invades the
central nervous system during primary infection. In
some cases, patients with acute HIV infection may pre-
sent with symptoms of aseptic meningitis, and pleocyto-
sis of the cerebrospinal fluid CSF is a frequent finding
among HIV patients [1]. Before the era of combined
active antiretroviral (ARV) therapy, a substantial number
of those patients who survived despite low levels of
CD4-positive lymphocytes developed AIDS dementia
complex (ADC) [2]. ARV treatment has dramatically
changed the life expectancy of HIV-infected patients,
and ADC is these days a rare diagnosis if patients are
adherent to treatment [3]. However, a number of
reports have described an apparent increase in preva-
lence of HIV-associated neurocognitive impairment
[2,4]. The clinical definitions of the various HIV-asso-
ciated conditions affecting the central nervous system
are not clear and potential pathogenic mechanisms are
not well understood [5]. Overlapping or common patho-
genic mechanisms, as those associated with other
neurodegenerative conditions, have been suggested. In a
small pilot study, we found that a surprisingly large frac-
tion of optimally treated HIV patients show minor
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metabolism in brain as visualized by fluorine-18-flouro-
deoxyglucose positron emission tomography (FDG-PET)
scanning [6]. These abnormalities resemble signs of
imminent neurodegeneration [7,8]. The aim of this
study was to perform cerebral FDG-PET scanning on a
larger number of patients, and to correlate potential
abnormalities with levels of circulating pro-inflammatory
cytokines that have been associated with neurodegenera-
tive conditions [9-11], and with a potential indicator of
neuro-regenerative/protective activities: brain derived
neurotrophic factor (BDNF) [12,13].
Methods
Study participants were recruited from an outpatient
clinic at a university hospital in Copenhagen, Denmark.
Around 1300 HIV patients are registered in the clinic
and around 80% receive ARV treatment. The treatment
guidelines are comparable to internationally accepted
recommendations and the treatment is free of charge
for the patients.
Inclusion criteria included age between 25 and 70 years
and verified HIV infection for at least 5 years. Patients
should have received ARV treatment for a minimum of 3
years with no virological failure. Virological failure was
defined as HIV RNA >400 copies/ml measured at two
consecutive samplings with a time spacing of at least two
weeks after having been fully suppressed earlier. The
CD4 count should be above 200 × 10
6 cells/l. The study
was a sub-study of a cohort of 100 patients enrolled ear-
lier [6]. The patients were enrolled sequentially for PET
scanning as they appeared in the outpatient clinic.
Exclusion criteria were anaemia (defined as a haemo-
globin concentration more than 1 mmol below the
lower limit of the normal range), hepatitis C infection,
elevated levels (>4 times the upper limit of normal) of
liver-derived transaminases, chronic renal failure (carba-
mide levels greater than 2× the upper limit of normal),
hypo- or hyper-thyroidism, focal neurological disease, I.
V. drug abuse, alcohol addiction, and other obvious or
serious co-morbidities. Also excluded were persons
unable to understand, read, and write the Danish lan-
guage, and pregnant or lactating women.
The following data were recorded from patient files:
age, sex, employment status, number of years of known
HIV infection, mode of HIV transmission, nadir CD4
count, maximum HIV RNA load, number of years on
antiretroviral therapy, number of years the patient
received “d-drugs“ i.e. stavudine and/or didanosin, pre-
sent ongoing treatment regimen, C-reactive protein
level, and thyroid-stimulating hormone level.
Serological analyses were performed on plasma sam-
ples, which had been stored at -80°C. Venous blood
samples were drawn into ethylenediaminetetraacetic
acid- (EDTA-) stabilized vacutainer® tubes (BD-Den-
mark, Brøndby, DK) and kept on wet ice. Plasma was
recovered by centrifugation within 30 minutes. BDNF
levels were measured by ELISA (R&D Systems, Minnea-
polis, MN, USA). After thawing, samples were centri-
fuged at 10000 × g for 10 minutes at 4°C for removal of
platelets. Samples were analysed in duplicate and mean
concentrations were calculated.
The levels of TNF-a and IL-6 were measured in com-
mercially available enzyme-linked-immunosorbent-assay
(ELISA) based kits (R&D systems Europe Ltd., Abing-
don, UK). suPAR levels were determined as described
earlier by a double-sandwich ELISA based on a murine
monoclonal anti-suPAR antibody as the catching anti-
body and a polyclonal rabbit antibody served as the
detecting antibody [14,15]. Colour reaction was obtained
after incubation with alkaline phosphatase-conjugated
anti-rabbit IgG (Sigma-Aldrich, Schnelldorf, FRG) using
p-nitrophenyl phosphate as the chromogen. All mea-
surements were performed in duplicate using either un-
diluted (TNF-a and IL-6) or diluted 1:10 (suPAR and
BDNF) sample. Serial dilutions of control antigen and
blanks were included on each plate.
Cerebral FDG-PET scanning
Patients fulfilling the inclusion criteria were invited to
have a cerebral FDG-PET scan. Recruitment was
stopped when 40 patients were enrolled. Two patients
were excluded after the scanning because they exhibited
focal lesions and it was verified that they had in fact
been treated for cerebral toxoplasmosis at another hos-
pital. The distribution of relative regional cerebral glu-
cose metabolic rate (rCMRglc) was measured using 18-
fluoro-deoxyglucose (FDG) PET scanning. PET scans
were performed with an eighteen-ring GE-Advance
scanner (General Electric Medical Systems, Milwaukee,
WI, USA) operating in 3D-acquisition mode, producing
35 image slices with an interslice distance of 4.25 mm.
The total axial field of view was 15.2 cm with an
approximate in-plane resolution of 5 mm [16]. Each
patient received an intravenous bolus injection of
approximately 200 MBq 18-FDG while resting in the
supine position with eyes covered and noise level kept
at a minimum. After 30 min the patient was placed in
the scanner, and the head fixed to restrict movements.
A 10 min transmission scan was performed for attenua-
tion correction followed by a 10 min 3-D emission scan.
PET images of the FDG distribution were reconstructed
using a 4.0 mm Hanning filter transaxially and an 8.5
mm Ramp filter axially.
Image analysis
Two strategies were used to evaluate the images designed
to identify pathological traits on an individual level as
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tion of the images for common features, but is a less
powerful approach in a setting dominated by heteroge-
neous findings. Initially each individual PET scan was
analysed using Neurostat, that allows direct visualization
of the extent and topography of FDG uptake abnormal-
ities [17]. This procedure involves the reconstruction of
the images with an 8-mm Hann filter, warping them to a
standard stereotactic space and projecting globally nor-
malized activity unto the cerebral surfaces. The surface
projects are subsequently compared voxel-by-voxel to 3
cohorts of age-matched groups of healthy subjects
depending on the patients’ age (19-34 years, 30-60 years,
and 55-90 years). This control material was not recruited
at our institution, but supplied with the Neurostat soft-
ware consisting of neurologically intact healthy volun-
teers [17]. The HIV status of this control group is not
known. Significant regional deviation from the mean was
expressed by a Z-score using a threshold value of Z >2.33
(p < 0.01, one sided) [17].
To supplement the individual evaluation of the PET
images we performed voxel-based image analysis using
statistical parametric mapping software (SPM5, Well-
come Department of Cognitive Neurology, London, UK;
http://www.fil.ion.ucl.ac.uk/spm/). The intent of this
strategy was explorative. The underlying assumption
was that a linear correlation exists in a regionally speci-
fic manner between cerebral activity in grey matter
structures and demographic or serologic parameters.
In all subjects the complete PET brain volume was
sampled. PET images were transformed into the stan-
dard stereotaxic atlas of Talairach and Tournoux [18]
using the PET template from Montreal Neurological
Institute, Canada (MNI). PET images were smoothed
with a 16-mm FWHM isotropic Gaussian kernel. The
differences in global activity were removed by ratio
adjustment, estimating global activity independently of
changes in local activity.
To identify statistically significant changes, repeated
statistical analyses were carried out using the general
linear model correlating a parameter of interest with
regional cerebral activity. As the analyses are explorative
and multiple non-independent comparisons are per-
formed it is necessary to set a stringent threshold value
that protects against false positive findings. A statistical
threshold was used at p < 0.05 (FDR, false discovery
rate) [19] corrected at the voxel level for multiple com-
parisons. The FDR has been validated and found useful
for imaging studies. It controls the expected proportion
of false positives among suprathreshold voxels. The
parameters analyzed were years of known HIV infection,
B D N F ,C R P ,n a d i rC D 4l e v e l ,T N F ,I L - 6 ,s u P A R ,m a x .
log. HIV RNA copies, and log transformed levels of
BDNF, TNF, IL-6, and suPAR.
Statistical analyses
Demographic and serological data were analysed using
SSPS version 13.0 for Windows. Mean values of the var-
ious parameters were compared group-wise in indepen-
dent sample t-tests. Pearson Chi-Square Test and
Fischer’s Exact Test s were used to assess potential cor-
relations between mode of HIV transmission and abnor-
mal PET scanning results. P values of < 0.05 were
considered significant and P values between 0.05 and
0.099 considered to be of borderline significance. Data
not normally distributed were log-transformed. Linear
correlations were analysed with Pearson correlations.
Ethical considerations
The project was approved by the Regional Committee
on Biomedical Research Ethics of Copenhagen and Fre-
deriksberg municipalities, reference number: (KF) 01-
192/03.
Results
A cohort of 38 HIV infected patients, optimally treated
with no virological failure for more than three years
underwent cerebral FDG-PET scanning. The patients
were carefully selected in order to include patients with
HIV as mono-morbidity. The patients were quite experi-
enced with known HIV infection for almost 12 years
(range 4 - 21 years) (table 1). Twenty-six patients (68%)
had part- or full time jobs and none had any overt neu-
rological manifestations. However, 21 (55%) of their cer-
ebral FDG PET-scanning images had focal abnormalities
when compared individually to age-matched controls.
These primarily consisted of metabolic reductions of
Table 1 Characteristics of study participants (n = 38)
Sex (n)
Males 32
Females 6
Ethnicity (n)
Caucasian 35
African 2
African-American 1
Mode of HIV infection (n)
Heterosexual 10
MSM
a 38
IVDU
b 0
Age 48.4 ± 9.2 (34-68)*
Years of known HIV infection 11.9 ± 4.9 (4-21)
Years on ARV therapy 7.7 ± 2.7 (3-16)
Years on didanosine and/or stavudine 1.5 ± 2.3 (0-7)
Nadir CD4 count (10
6 cells/l) 190 ± 188 (10-740)
Maximum HIV RNA (log copies/ml)
C 5.2 ± 0.6 (3.6-6.4)
a MSM: males having sex with males;
b IVDU: intra-venous drug users;
c data
only available for 30 patients
* Data expressed as mean ± SD (range)
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the anterior cingulated cortex (Figure 1). The mesial
frontal lobes are targeted in a number of different neu-
ronal pathologies. Thus, it is a prominent feature of
neurodegenerative disease, particularly frontotemporal
dementia (FTD) [20], and of neuropsychiatric systemic
lupus erythematosus (SLE) [21].
The correlates of the PET abnormalities are sum-
marised in table 2. The PET scanning abnormalities
were correlated with age, as the patients with abnormal
PET scanning results were slightly older (mean age 49.9
years) than those with a normal PET scanning (mean
age 46.6 years, p = 0.3). However, the age effects were
controlled for in the Neurostat analysis by comparing
patients with age-matched healthy controls. The patients
with abnormal cerebral FDG-PET scanning had been
aware of their HIV infection for fewer years (10.3 vs.
13.8 years, p = 0.03) and had received ARV treatment
for a shorter time period (7 vs. 8.5 years, p = 0.08) than
the patients with normal FDG-PET cerebral brain scan-
ning results. None of the patients had any reported IV
drug abuse (which would have excluded them from the
study) and there was no correlation between mode of
HIV transmission and an abnormal PET scanning result
(Person Chi Square and Fischer’s Exact Test p = 0.3).
No difference in exposure to potential mitochondrio-
toxic agents like didanosine and/or stavudine could be
demonstrated. The patients had received a variety of
ART regimens for various time spans over the years,
thus not allowing comparison of neuropenetrating regi-
mens with less neuropenetrating regimens. The mean
nadir CD4 count of the group with normal PET scan-
ning was lower than in the group with abnormal PET
scans, but this difference was not statistically significant
(p = 0.1). We would have expected a lower CD4 nadir
in the group exhibiting PET abnormalities but noted
that the nadir levels were quite low in both groups. The
patients with FDG-PET scanning abnormalities had
higher levels of circulating TNF a (p = 0.08) and IL-6
(p = 0.08) but no differences were observed in the levels
of BDNF or suPAR (table 3). In bivariate analyses the
suPAR and TNF a levels correlated with a Pearson coef-
ficient of 0.29 (p = 0.08), but no correlation was
observed among the other parameters measured. The
SPM analyses correlating demographic and serological
Figure 1 Maximum Z-score maps from 3 individuals compared to a group of healthy controls using the Neurostat software.S u r f a c e
projections display the Z-score maps from lateral, superior, inferior, anterior, posterior, and medial views. The images are scaled from -4.0 to 4.0
in Z-scores with the warm colours representing areas that are more active than the control group, and the cold areas representing areas that are
less active. Subject a) was evaluated as normal, subject b) as possibly abnormal, and subject c) as abnormal. The arrows point to significant
reductions in the medial frontal cortices.
Table 2 Demographics, HIV history and FDG-PET
scanning results
Normal PET
n=1 7
Abnormal
PET
n=2 1
p-value
a
Mean ± SD Mean ± SD
Age (y) 46.6 ± 8.4 49.9 ± 9.8 0.3
Years of known HIV infection 13.8 ± 5.2 10.3 ± 4.2 0.03*
Nadir CD4 level (10
6 cells/l) 134 ± 144 236 ± 210 0.1
Max. log. HIV RNA copies/ml
b 4.97 ± 0.7 5.34 ± 0.6 0.12
Years on ARV treatment 8.5 ± 3.3 7 ± 2 0.08*
Years on didanosine and/or
stavudine
1.3 ± 1.9 1.7 ± 2.7 0.6
ap values, equal variance of means assumed,
b data only available for 30
patients
*p-values < .05 considered significant, values between .05 -.099 considered
borderline significant
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not reveal any statistically significant findings. This
widely used technique is designed to identify a common
pattern of variation within or between groups. The lack
of significant findings may reflect a combination of a
relatively weak signal change and heterogeneity in the
pattern of affected cortical regions.
Discussion
The patients included in this study were carefully
screened for co-morbidities and fulfilled criteria for opti-
mal ARV treatment: fully suppressed viral loads in
plasma and a CD4 level above 200 × 10
6 cells/l for a
minimum of three years. In fact, the mean number of
years on ARV was 7.7 for the entire group and more
than 68% were working full- or part time at the time of
the study. Surprisingly, half of these well functioning
patients exhibited cerebral FDG-PET scanning abnorm-
alities associated with increased levels of circulating
TNF a and IL-6 (p = 0.08). Other studies have demon-
strated an association between circulating levels of TNF
a and IL-6 in neurodegenerative conditions [9,22]. How-
ever, these functional associations have been heteroge-
neous, and we could not from our data demonstrate a
consistent pattern that systematically associated TNF a
or IL-6 levels with a defined set of grey matter
structures.
suPAR levels have previously been found to be
increased in patients with ADC or opportunistic CNS
infections [23,24]. The abnormalities described by FDG-
PET scanning are probably only a very early sign of suf-
fering neurons, and overt cell damage may not necessa-
rily have occurred yet. This could explain why suPAR
and BDNF levels were not correlated with the scanning
results.
HIV 1 enters the central nervous system very early in
HIV infection, and it is well established that HIV plays a
role in late-stage disease with severe immuno-suppres-
sion and high viral loads. It is however still a matter of
debate whether continued viral replication as measured
in peripheral blood reflects conditions inside the blood-
brain barrier (BBB) and, most importantly, whether it
harms the brain [25-27]. Among the potential problems
related to ARV therapy is the difference in drug concen-
trations achieved in the CSF compared to peripheral
levels - leaving the CNS as a sanctuary site.F u r t h e r -
more, some ARV drugs are toxic to the g polymerase of
mitochondria, rendering cells with low-level metabolic
activity susceptible to this toxic impact [28]. It was not
possible in this study to demonstrate a neurodamaging
effect that correlated with use of these drugs. Several
explanations may be thought of e.g. too small a sample
size or too short an exposure.
A recent prospective MRI study reported signs of fas-
t e rg r e ya n dw h i t em a t t e rv o l u m el o s si nH I V - p o s i t i v e
patients (in adequately treated patients as well as in
patients with detectable viraemia) compared to HIV-
negative patients [29]. The authors do not offer an
explanation but suggest that the cognitive function of
HIV patients receiving ARV treatment should be
monitored.
Conclusion
A substantial fraction of optimally treated HIV patients
exhibit metabolic abnormalities of cerebral glucose
metabolism, which may represent imminent neuronal
damage. This group of patients had been aware of their
HIV infection and had been on ARV for fewer years
than those patients without abnormalities. It could be
speculated that these patients have suffered longer brain
exposure to high HIV loads than those without abnorm-
alities. The potential neuroprotective effect of early ARV
treatment should be considered but further studies and
prospective follow-up studies including detailed neurop-
sychological testing are needed to evaluate the clinical
implications of these results.
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